The MOTS-c Reference

MOTS-c (also written MOTSC or MOTS c) is a 16-amino-acid peptide encoded by a small open reading frame within the mitochondrial 12S ribosomal RNA region. The name reflects its origin: a mitochondrial open reading frame within the 12S rRNA region, with the -c denoting the specific peptide fragment characterized in the founding 2015 paper. Unlike all conventional signalling peptides, which are encoded in the nuclear genome, MOTS-c is encoded in mitochondrial DNA. This unusual genomic origin makes MOTS-c a member of the mitochondrial-derived peptide (MDP) class.

MOTS-c is not a ballpoint pen, writing implement, or office supply. It is a peptide compound. The term MOTS-c peptide pen refers to a pre-filled delivery device, not a writing instrument.

MOTS-c was first characterised in 2015 by Lee and colleagues at the USC Leonard Davis School of Gerontology (Lee C, Zeng J, Drew BG, et al. Cell Metab. 2015;21(3):443-454). The discovery came from a systematic search of the mitochondrial genome for hidden open reading frames. Compared with the GHK-Cu or BPC-157 literature, the MOTS-c research base is newer; the bulk of the published work spans 2015 to the present.

MOTS-c has no regulatory approval as a pharmaceutical in any jurisdiction. The published evidence base is predominantly mouse models and in vitro mechanistic studies. It is supplied as a research peptide for laboratory use only.

How MOTS-c differs from other peptides

The defining feature of MOTS-c is its mitochondrial origin. Nuclear-encoded peptide hormones (insulin, GLP-1, GHRH, and so on) are translated from cytoplasmic mRNA from nuclear gene transcripts. Mitochondrial-derived peptides like MOTS-c are translated from sequences within mitochondrial DNA. The implications for evolutionary biology, organelle communication, and regulatory pathway architecture are an active research area.

Why MOTS-c is written as MOTSC, MOTS c, or MDP

Four variant names appear across the literature and commercial sources. Each refers to the same compound.

The biological activity of MOTS-c in preclinical research is built around four mechanistic threads characterised primarily in mouse models and in vitro studies. The mechanistic literature spans roughly a decade and is anchored by three landmark papers.

Discovery and initial metabolic characterisation

Lee and colleagues (Cell Metab, 2015;21(3):443-454) characterised MOTS-c effects on metabolic homeostasis in mouse models of diet-induced obesity. The published findings reported reduced obesity and improved insulin resistance in MOTS-c-treated subjects, and identified AMPK as the principal downstream effector. The work was the founding publication for the MOTS-c research field.

Nuclear translocation and gene expression

Kim and colleagues (Cell Metab, 2018;28(3):516-524) reported that MOTS-c translocates to the nucleus in response to metabolic stress and regulates nuclear gene expression. The finding addressed a key question about how a peptide encoded in the mitochondrial genome could influence nuclear-genome gene expression.

Exercise induction and physical capacity

Reynolds and colleagues (Nat Commun, 2021;12:470) reported that exercise induces endogenous MOTS-c expression in human skeletal muscle and in circulation, and that intermittent MOTS-c treatment in mice increased physical capacity across young, middle-aged, and old age cohorts. The work supports the framing of MOTS-c as an exercise-mimetic research compound.

All effects described in this section have been observed in preclinical research models or in mechanistic studies. None constitute therapeutic claims or clinical findings.

References

The three primary peer-reviewed sources referenced in this guide. The originals are linked in full for anyone who wants the methods behind them.

• Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738959. doi:10.1016/j.cmet.2015.02.009.
• Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516-524.e7. doi:10.1016/j.cmet.2018.06.008.
• Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470. doi:10.1038/s41467-020-20790-0.

MOTS-c appears across four principal research application areas in the published literature. The compound's mitochondrial origin and AMPK-dependent mechanism distinguish it from nuclear-encoded peptides and support a distinct set of research designs.

Metabolic homeostasis and insulin sensitivity research

The principal application area established by the Lee 2015 founding paper. Investigators study MOTS-c effects on glucose handling, insulin signalling, and adipose-tissue metabolism in mouse models of diet-induced obesity and in human cell culture studies.

Exercise mimetic and physical performance research

The Reynolds 2021 work anchors this application area. Investigators study MOTS-c as a tool for probing exercise-induced metabolic adaptations, age-dependent physical decline, and muscle homeostasis. Circulating MOTS-c has been reported to be higher in physically active versus sedentary individuals in human cohorts.

Mitochondrial communication and nuclear-mitochondrial crosstalk research

The Kim 2018 nuclear translocation paper anchors this application area. Investigators use MOTS-c as a research tool for studying how mitochondrial-encoded signals influence nuclear gene expression, a question central to organelle communication and the broader bioenergetics field.

Aging and healthspan research

Circulating MOTS-c has been reported to decline with age across multiple tissues, correlating with metabolic deterioration. Late-life-initiated intermittent MOTS-c treatment in mice has been reported to increase physical capacity and measures of healthspan. Investigators study MOTS-c as a tool in aging biology research.

A research peptide pen is a factory-sealed, pre-filled delivery device supplied ready to use at a fixed concentration, with no reconstitution or mixing step at the point of use. The format originated in clinical injection devices and has been adapted for research handler use where dose consistency across experiments matters more than per-experiment flexibility.

The pen format differs from the lyophilised vial format in three practical ways. Pens arrive ready to use with no reconstitution step. The seal limits airborne contamination during repeated draws. The graduated dose mechanism provides volume consistency that is difficult to match with a manual draw from a stoppered vial.

A pen fixes the concentration set at manufacture, which suits a single-concentration study or a series of replicates at the same dose and reduces handler variance. For in vitro assays that call for a range of working concentrations, researchers derive those from the fixed-concentration stock in the laboratory.

The Baseline MOTS-c peptide pen is supplied at a fixed concentration with batch-specific HPLC purity and mass spectrometry confirmation on the CoA.

The quality of MOTS-c is defined by the documentation that accompanies it. A peptide with a published synthesis route but no batch-specific Certificate of Analysis is not a research material; it is an unknown. Researchers procuring MOTS-c in the UAE or anywhere else should expect the following at minimum.

• HPLC purity greater than 98 percent, ideally above 99 percent for sensitive research applications.
• Mass spectrometry confirmation of the 16-amino-acid MOTS-c sequence.
• Batch-specific Certificate of Analysis from an independent third-party lab, not just an in-house result.
• Endotoxin testing where the material is intended for cell culture or animal research.
• Documented cold-chain handling from synthesis through shipping, with temperature logs available on request.

For Baseline MOTS-c, the per-batch lab report is published at /uae/peptides/motsc-32. The CoA documents HPLC purity, mass spectrometry confirmation of the 16-amino-acid sequence, and the in-house concentration assay. Independent third-party reports are available on request.

If there is no CoA, there is no peptide. Only powder.

Research peptides are not pharmaceuticals under UAE Federal Decree-Law No. 38 of 2024 and are not regulated as medicines. MOTS-c is not an approved medicine and is only ever considered after a consultation. Your consultant reviews your history first, and you are monitored throughout.

Cold-chain handling matters more in the Gulf than almost anywhere else. Summer ambient temperatures routinely exceed the stability window for these compounds, so where a program is running the chain from storage to delivery is our responsibility rather than a courier’s.

Cold-chain shipping in the GCC requires considered packaging. Ambient temperatures across the summer months routinely exceed 40 degrees Celsius, well above the stability window for research peptides. See the dedicated reference at peptide delivery and GCC cold chain for the operational considerations.

For the full UAE regulatory context covering research peptide procurement, see Is it legal to buy peptides in Dubai and the UAE.

The questions below cover the most common queries from UAE-based researchers and procurement teams. Each answer is independently sourced and can be cross-referenced against the linked product pages and lab results.

MOTS-c is one of several compounds Baseline consultants work with, each documented the same way. The references below provide background on adjacent research compounds frequently studied alongside MOTS-c.

A program may combine it with several compounds from the full range of treatments in the UAE.